Oral Salmon Calcitonin

Global annual sales of nasal product currently = $500 M ($1B peak)
Long term toxicology study completed; long term carcinogenicity study protocol approved
Phase II Study of 3 months dosing duration completed
- no SAEs reported
- data is currently being analyzed by Novartis
Additional manufacturing, formulations and packaging work done by NVS
Update from NVS on next steps (1H03)